Navigation Links
BioLife Solutions Announces Presentation at IBC Inaugural Cell Therapy Clinical Development Conference
Date:9/12/2012

BOTHELL, Wash., Sept. 12, 2012 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced its participation at the IBC Inaugural Cell Therapy Clinical Development Conference taking place this week in Arlington, VA.

(Logo: http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)

Dr. Aby J. Mathew, Senior Vice President and Chief Technology Officer, presented a lecture to dozens of executives and product development managers of commercial regenerative medicine companies. The presentation, titled, Optimizing Stability and Biopreservation for Cell Therapy Clinical Development and Bioprocessing, exposed the risk to clinical and commercial success of cell and tissue products due to stability limitations from the use of non-optimized storage, transport and cryopreservation freeze media. Compelling comparative data illustrating the superior preservation efficacy of BioLife's HypoThermosol® storage and shipping media, and CryoStor® cryopreservation freeze media was presented on a broad spectrum of cell and tissue types.

Mike Rice, Chief Executive Officer, commented on BioLife's presence and leading supplier position within the regenerative medicine market: "Our participation at this event was validated by numerous other presenters for the first time, confirming to their peers and competitors that they have adopted our best-in-class biopreservation media products.  We estimate that more than 60 percent of the companies registered to attend or present are current customers.  It's very satisfying to see our quality environment and the ability of our products to improve cell-based therapies being recognized by the leaders in commercial cell therapy development."

For a list of upcoming events, please visit: http://biolifesolutions.com/cell-therapy/category/events/

About BioLife Solutions

BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells and tissues.  The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are marketed to academic and commercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced, delayed-onset cell damage and death.  BioLife's enabling technology provides academic and clinical researchers significant improvements in post-thaw cell, tissue, and organ viability and function.  For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact.  Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission.  BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.  Media Relations:

Investor Relations:Len Hall

Matt ClawsonAllen & Caron Inc

Allen & Caron Inc(949) 474-4300

(949) 474-4300len@allencaron.com

matt@allencaron.com
'/>"/>

SOURCE BioLife Solutions, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
2. BioLife Solutions 2011 Revenue Up 33%
3. BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board
4. Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION
5. BioLife Solutions Completes Corporate Facilities Expansion, Build-Out of Additional cGMP Clean Room Manufacturing Suite
6. BioLife Solutions Announces 2012 Second Quarter Results: Eighth Straight Quarter of Record Revenue
7. Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany
8. ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents
9. Elsevier Acquires QUOSA, Provider of Life Sciences Content Management and Workflow Productivity Solutions
10. Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes
11. Psyche Systems Corporation Signs Strategic Alliance with Siemens Healthcare to Provide Anatomic Pathology Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Md. and GAITHERSBURG, Md. ... (NYSE MKT: PIP) and Altimmune, Inc., a privately-held ... signing of a definitive agreement for the merger ... Altimmune,s current investors include Novartis Venture Fund, HealthCap, ... will be a fully-integrated and diversified immunotherapeutics company ...
(Date:1/19/2017)... -- AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: AQB), a ... a majority-owned subsidiary of Intrexon Corporation (NYSE: ... of its common shares on the NASDAQ Stock Market ... "AquaBounty,s listing on NASDAQ represents an important milestone for ... U.S. markets as we advance plans for commercial production ...
(Date:1/19/2017)... Linda, Ca (PRWEB) , ... January 18, 2017 ... ... virtual events for tech innovators, engineers, and scientists from around the world, was ... American News. The awards program is based entirely on merit and decided upon ...
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical Research ... drug and device development, and Prism Clinical Research , a leader in ... Verified Clinical Trials (VCT) has been selected by both companies as ...
Breaking Biology Technology:
(Date:1/18/2017)...  In vitro diagnostic (IVD) companies were very active ... and Kalorama Information expects that trend to continue – ... Generally, uncertainty in reimbursement and healthcare reform in ... the acquisitions landscape. Instead of looking to buy technology, ... outside of their home country and also to increase ...
(Date:1/12/2017)... 12, 2017 A new report by Allied Market Research, titled, ... biometric technology market is expected to generate revenue of $10.72 billion by 2022, with ... Continue Reading ... Allied Market Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) In the ...
(Date:1/6/2017)... , Jan. 5, 2017  Delta ID Inc., a ... scanning technology for automotive at CES® 2017. Delta ID ... ) to demonstrate the use of iris scanning as ... authenticate the driver in a car, and as a ... driving experience. Delta ID and Gentex will ...
Breaking Biology News(10 mins):